Clinical Trial Update: GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) [EARLY_Phase 1]

View source ↗

Summary

An early-phase 1 trial of GCAR1, a GPNMB-targeting CAR T-cell therapy, for alveolar soft part sarcoma; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma

Drugs mentioned

• GCAR1 (GPNMB-targeting CAR T-Cell Therapy)

Snippet

Sponsor: AHS Cancer Control Alberta | Conditions: Alveolar Soft Part Sarcoma | EARLY_Phase 1 | Status: ACTIVE_NOT_RECRUITING